AMD Q3 adjusted EPS preliminary data at $0.29-$0.31, analyst expectation at $0.53.

AMD Q3 adjusted EPS preliminary data at $0.29-$0.31, analyst expectation at $0.53.

Centene Corporation (NYSE: CNC) announced its financial results for the first quarter ended March 31, 2025, highlighting robust growth across its premium and service revenues. The company reported an adjusted diluted EPS of $2.90, representing a 28% increase from the same period last year [1].

Key highlights from the quarter include:

- Revenue Growth: Premium and service revenues increased by 17% to $42.5 billion, driven by strong performance in the Medicare Prescription Drug Plan (PDP) business and the Marketplace segment.
- Membership Growth: Membership in Marketplace and Medicare PDP increased by 29% and 22% respectively, compared to the first quarter of 2024.
- Operational Efficiency: The SG&A expense ratio decreased to 7.9%, reflecting cost efficiencies and growth in the PDP business.

Centene's Chief Executive Officer, Sarah M. London, stated, "Our first quarter results demonstrate the resiliency of Centene's platform and the progress we are making as an organization while navigating a dynamic policy landscape."

The company also secured significant contracts for its subsidiaries, including SilverSummit Healthplan and Meridian Health Plan, to continue providing services for Medicaid and Medicare programs in Nevada and Illinois, respectively.

AMD Q3 Adjusted EPS Preliminary Data

In contrast, Advanced Micro Devices (AMD) reported its Q3 adjusted EPS preliminary data at $0.29-$0.31, falling short of analyst expectations of $0.53 [2]. This discrepancy underscores the varied performance across the healthcare and technology sectors.

References

[1] Centene Corporation. (2025, April 25). Centene Corporation Reports First Quarter 2025 Results. Retrieved from https://investors.centene.com/2025-04-25-CENTENE-CORPORATION-REPORTS-FIRST-QUARTER-2025-RESULTS

[2] AMD. (2025, April 30). AMD Q3 Adjusted EPS Preliminary Data. Retrieved from https://www.amd.com/press/press-releases/2025-q3-adj-eps-preliminary-data